Omalizumab (XOLAIR) ELISA Assay Kit
The Omalizumab (XOLAIR) ELISA Assay Kit is For Research Use Only
Size: 12 x 8 wells
Sensitivity: 10 ng/mL
Standard Range: 0 – 1,000 ng/mL
Incubation Time: 1 hour 10 minutes
Sample Type: Serum, Plasma
Sample Size: 20 uL
Alternative Name: Xolair
Assay Background
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) which treats the symptoms of asthma and chronic idiopathic urticaria by limiting the allergic response. It inhibits the binding of IgE to receptors on mast cells and basophils, blocking the IgE-mediated secretion of inflammatory mediators from these cells. Mast cell activation and the release of mediators, in response to allergen exposure and IgE, results in a cascade of events. This cascade culminates in the activation of B-lymphocytes, T-lymphocytes, eosinophils, fibroblasts, smooth muscle cells, and the endothelium. This cellular interaction, as well as the release of cytokines, chemokines and growth factors and inflammatory remodeling of the airway results in chronic asthma.
Assay Principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtiter plate coated with the reactant for omalizumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to omalizumab captured by the reactant on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of omalizumab in the sample or standard. Results of samples can be determined directly using the standard curve.
Related Products
Anti-Omalizumab (Xolair) ELISA
Omalizumab mAb-Based ELISA Assay
